Journal Article

A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II–IIIA non-small cell lung cancer: study protocol for a randomized controlled trial

Ito, Suminobu, Kitagawa, Chiyoe, Saito, Akiko M., Shimokawa, Mototsugu, Nagashima, Seiji, Fukuyama, Seiichi, Takami, Koji, Oka, Tadayuki, Maeda, Tadashi, Yoshimoto, Kentaro, Kato, Tatsuo, Saka, Hideo, Okabayashi, Kan, Yamashita, Motohiro, Ichinose, Yukito, Kouso, Hidenori, Takeo, Sadanori, Ueda, Hitoshi, Takenoyama, Mitsuhiro, Ibata, Hidenori

2017

Overview

Background As the toxicity associated with the α-GalCer-pulsed dendritic cell (DC) therapy could be considered to be negligible, its addition to postoperative adjuvant chemotherapy would be expected to greatly improve the therapeutic effect, and could result in prolonged survival. The aim of the present study is to compare the therapeutic efficacy of alpha-galactosylceramide-pulsed DC therapy in patients who have undergone a complete resection of stage II–IIIA non-small-cell lung cancer (NSCLC) followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to that in patients who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only). Methods Subsequent to the complete resection of NSCLC, followed by the administration of cisplatin plus vinorelbine dual-agent combination adjuvant chemotherapy, patients who satisfy the inclusion criteria will be randomly allocated to either the α-GalCer-pulsed DC immune therapy group, or the standard treatment group. In total, 56 patients will be included in the study. The primary endpoint is recurrence-free survival, and the secondary endpoints are natural killer T-cell-specific immune response, the frequency of toxic effects and safety, and overall survival. Discussion In order to determine the efficacy of α-GalCer-pulsed DC therapy, the present study compares patients with stage II–III NSCLC who underwent complete surgical resection followed by postoperative adjuvant therapy with cisplatin plus vinorelbine, to those who did not receive additional treatment (surgical resection plus postoperative adjuvant chemotherapy only). Trial registration UMIN000010386 ( R000012145 ). Registered on 1 April 2013. UMIN-CTR is officially recognized as a registration site which satisfies ICMJE criteria.

• Publisher: BioMed Central,Springer Nature B.V,BMC
• Subject: Adult / Aged / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Biomedicine / Cancer therapies / Carcinoma, Non-Small-Cell Lung - immunology / Carcinoma, Non-Small-Cell Lung - mortality / Carcinoma, Non-Small-Cell Lung - pathology / Carcinoma, Non-Small-Cell Lung - therapy / Chemotherapy / Chemotherapy, Adjuvant / Cisplatin - administration & dosage / Clinical Protocols / Clinical trials / Dendritic cells / Dendritic Cells - drug effects / Dendritic Cells - immunology / Dendritic Cells - transplantation / Disease-Free Survival / Female / Galactosylceramides - adverse effects / Galactosylceramides - therapeutic use / Health Sciences / Hospitals / Humans / Immunology / Immunotherapy / Immunotherapy, Adoptive - methods / Japan / Ligands / Lung cancer / Lung Neoplasms - immunology / Lung Neoplasms - mortality / Lung Neoplasms - pathology / Lung Neoplasms - therapy / Lymphocytes, Tumor-Infiltrating - immunology / Male / Medicine / Medicine & Public Health / Middle Aged / Mortality / Natural Killer T-Cells - immunology / Neoplasm Recurrence, Local / Neoplasm Staging / Non-small cell lung cancer / Patients / Phase II / Pneumonectomy - adverse effects / Research Design / Statistics for Life Sciences / Study Protocol / Time Factors / Toxicity / Treatment Outcome / Vinblastine - administration & dosage / Vinblastine - analogs & derivatives / Young Adult